Literature DB >> 17276841

Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma.

Nicole J Watring1, Thomas W Wagner, James J Stark.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17276841     DOI: 10.1016/j.ajem.2006.10.005

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


× No keyword cloud information.
  12 in total

1.  Abdominal aortitis after use of granulocyte colony-stimulating factor.

Authors:  Giridhar U Adiga; Dahlia Elkadi; Sandeep K Malik; Jill D Fitzpatrick; Stefan Madajewicz
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

2.  Ten-year review of isolated spontaneous mesenteric arterial dissections.

Authors:  Courtney E Morgan; Neel A Mansukhani; Mark K Eskandari; Heron E Rodriguez
Journal:  J Vasc Surg       Date:  2017-11-13       Impact factor: 4.268

3.  Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.

Authors:  Ruth Pettengell; Peter Bias; Udo Mueller; Nicole Lang
Journal:  Support Care Cancer       Date:  2016-01-16       Impact factor: 3.603

Review 4.  Hematopoietic growth factors: personalization of risks and benefits.

Authors:  Shannon Puhalla; Saveri Bhattacharya; Nancy E Davidson
Journal:  Mol Oncol       Date:  2012-03-20       Impact factor: 6.603

5.  Acute abdomen due to spontaneous splenic rupture as the first presentation of lung malignancy: a case report.

Authors:  Angelos Kyriacou; Nolan Arulraj; Haren Varia
Journal:  J Med Case Rep       Date:  2011-09-07

6.  Neutrophil-Lymphocyte Ratio Is Associated With Occurrence of Febrile Neutropenia in Patients Treated With 5-Fluorouracil and Cisplatin.

Authors:  Satomi Kumazawa; Tomohiro Mizuno; Naoyuki Muramatsu; Masakazu Hatano; Takenao Koseki; Hiroshi Matsuoka; Koichi Suda; Ichiro Uyama; Shigeki Yamada
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

7.  Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial.

Authors:  Matteo Lambertini; Paolo Bruzzi; Francesca Poggio; Simona Pastorino; Giovanni Gardin; Matteo Clavarezza; Claudia Bighin; Paolo Pronzato; Lucia Del Mastro
Journal:  Support Care Cancer       Date:  2015-08-27       Impact factor: 3.603

Review 8.  Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.

Authors:  Geralyn E Waters; Patricia Corrigan; Mandy Gatesman; Thomas J Smith
Journal:  J Oncol Pract       Date:  2012-11-06       Impact factor: 3.840

Review 9.  613 cases of splenic rupture without risk factors or previously diagnosed disease: a systematic review.

Authors:  F Kris Aubrey-Bassler; Nicholas Sowers
Journal:  BMC Emerg Med       Date:  2012-08-14

10.  Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature.

Authors:  Nehal Masood; Asim Jamal Shaikh; Wasim Ahmed Memon; Romana Idress
Journal:  Cases J       Date:  2008-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.